Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Treatment Resistant Depression
Interventions
DRUG

Placebo

Placebo administered twice per day for six weeks.

DRUG

CX157 (TriRima)

One tablet administered twice per day (total daily dose of 250 mg) for six weeks.

Trial Locations (30)

10021

Eastside Comprehensive Medical Center, New York

18915

Introspect of Buxmont, Ltd, Colmar

27609

Richard H. Weisler, M.D. and Associates, Raleigh

30080

Nathan Shapira, MD, Ph.D, Smyrna

30328

Atlanta Institute of Medicine and Research, Atlanta

32216

Clinical Neuroscience Solutions, Inc., Jacksonville

32789

Kolin Research Group, Winter Park

32806

Clinical Neuroscience Solutions, Inc., Orlando

33161

The Segal Institute of Clinical Research, North Miami

33163

University of South Florida College of Medicine Psychiatry Center, Tampa

33613

Stedman Clinical Trials, Tampa

33912

Gulfcoast Clinical Research Center, Fort Myers

38119

Clinical Neurosciences Solutions, Inc., Memphis

44122

NorthCoast Clinical Trials, Inc., Beachwood

44130

North Star Medical Research, LLC, Middleburg Heights

45215

Patient Priority Clinical Sites, LLC, Cincinnati

53223

Northbrooke Research Center, Deer Brown

75231

FutureSearch Trials of Dallas, Dallas

78754

Community Clinical Research, Inc., Austin

84123

Radiant Research, Murray

91950

Synergy Clinical Research Center, National City

92025

Synergy Escondido, Escondido

92056

Excell Research, Oceanside

92868

Pacific Clinical Research, Orange

97210

Oregon Center for Clinical Investigations, Inc, Portland

Summitt Research Network (Oregon), Portland

98007

Northwest Clinical Research Center, Bellevue

98104

Summit Research Network (Seattle) LLC, Seattle

02478

McLean Hospital, Belmont

02721

AccelRx Research, Fall River

Sponsors
All Listed Sponsors
lead

CeNeRx BioPharma Inc.

INDUSTRY

NCT01246908 - Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression | Biotech Hunter | Biotech Hunter